In Vitro Activities of New Antimicrobials against Nocardia brasiliensis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 602-604

  Vera Cabrera, Lucio ^a,c   Gonzalez, Eva ^a   Choi, Sung H ^b   Welsh, Oliverio ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Dong A Pharmaceutical Company   (South Korea)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; DA 7867; DA-7867; GARENOXACIN; GATIFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; DRUG EFFECT; HUMAN; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NOCARDIA; NOCARDIA BRASILIENSIS; NOCARDIOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; NOCARDIA; NOCARDIA INFECTIONS; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SULFONAMIDES;

EID: 0942279621     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.602-604.2004     Document Type: Article

References (14)

1. Brown-Elliott, B. A., S. C. Ward, C. J. Crist, L. B. Mann, R. W. Wilson, and R. J. Wallace, Jr. 2001. In vitro activities of linezolid against multiple Nocardia species. Antimicrob. Agents Chemother. 45:1295-1297.
2. Clemett, D., and A. Markham. 2000. Linezolid. Drugs 59:815-827.
3. Diekema, D. I., and R. N. Jones. 2000. Oxazolidinones: a review. Drugs 59:7-16.
4. Lerner, P. I. 1996. Nocardiosis. Clin. Infect. Dis. 22:891-905.
5. López-Martínez, R., L. J. Méndez-Tovar, P. Lavalle, O. Welsh, A. Saul, and E. Macotela-Ruíz. 1992. Epidemiología del micetoma en México: estudio de 2105 casos. Gac. Med. Mex. 128:477-481.
6. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Document M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. Moylett, E. H., S. E. Pacheco, B. A. Brown-Elliott, T. R. Perry, E. S. Buescher, M. C. Birmingham, J. J. Schentag, J. F. Gimbel, A. Apodaca, M. A. Schwartz, R. M. Rakita, and R. J. Wallace, Jr. 2003. Clinical experience with linezolid for the treatment of nocardia infection. Clin. Infect. Dis. 36:313-318.
8. Noskin, G. A., F. Siddiqui, V. Stosor, D. Hacek, and L. R. Peterson. 1999. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 43:2059-2062.
9. Valera, L., E. Gradelski, E. Huczko, T. Washo, H. Yigit, and J. Fung-Tomc. 2002. In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J. Antimicrob Chemother. 50:140-142.
10. Vera-Cabrera, L., A. Gomez-Flores, W. G. Escalante-Fuentes, and O. Welsh. 2001. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis. Antimicrob. Agents Chemother. 45:3629-3630.
11. Weller, T. M., J. M. Andrews, G. Jevons, and R. Wise. 2002. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J. Antimicrob. Chemother. 49:177-184.
12. Welsh, O., E. Sauceda, J. González, and J. Ocampo. 1987. Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. J. Am. Acad. Dermatol. 17:443-448.
13. Welsh, O. 1991. Mycetoma: current concepts in treatment. Int. J. Dermatol. 30:387-398.
14. Welsh, O., M. C. Salinas, and M. A. Rodríguez. 1994. Mycetoma, p. 1402-1406. In P. D. Hoeprich, M. C. Jordan, and A. R. Ronald (ed.), Infectious diseases, 5th ed. J. B. Lippincott Company, Philadelphia, Pa.